Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Zhongshan Hospital
This is an observational cross-sectional retrospective study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Consistent with the "Chinese Medical Association Guidelines for the Diagnosis and Treatment of Lung Cancer (2018 Edition)," histologically confirmed as NSCLC;
2. According to the 8th edition of the AJCC TNM staging system, it is stage III B to IV and not suitable for surgery;
3. Age ≥18 years;
4. First-time recipients of immunotherapy combined with chemotherapy;
5. Baseline data within 1 month before the start of treatment is complete (at least including chest CT, pulmonary function, and laboratory tests);
6. At least 1 measurable lesion according to RECIST 1.1;
7. Receiving immune checkpoint inhibitor therapy for more than 2 cycles;
8. Clinical data is complete.
You may not be if
1. Presence of other malignant tumors;
2. Previous exposure to immunotherapy or systemic chemotherapy;
3. Patients with severe dysfunction of vital organs (heart, liver, lungs, kidneys) and bone marrow at baseline;
4. Presence of severe infectious diseases, active autoimmune diseases, or immune deficiencies that significantly affect immune function;
5. Organ transplantation;
6. Pregnant or lactating women;
7. Incomplete clinical treatment or follow-up information.
